142 related articles for article (PubMed ID: 35033478)
21. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706
[TBL] [Abstract][Full Text] [Related]
22. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.
Cho JY; Jang SC; Kang DW; Lee EK; Koh H; Yoon DH; Park MH
Front Oncol; 2024; 14():1282323. PubMed ID: 38361777
[TBL] [Abstract][Full Text] [Related]
23. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
24. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
27. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.
MacEwan JP; Batt K; Yin W; Peneva D; Sison S; Vine S; Chen C
Leuk Lymphoma; 2018 Apr; 59(4):941-949. PubMed ID: 28805105
[TBL] [Abstract][Full Text] [Related]
28. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
29. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
[No Abstract] [Full Text] [Related]
30. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bento L; Gutiérrez A; Novelli S; Montoro J; Piñana JL; López-Corral L; Cabrero M; Martín-Sancho A; Gutiérrez-García G; Ortiz-Moscovich M; Bastos-Oreiro M; Dorado N; Pérez A; Hernani R; Ferrà C; Parody R; García-Cadenas I; Herrera P; Rodríguez G; Rodríguez N; Martín C; Yáñez L; Zanabili J; Varela MR; López-Godino O; Heras I; Español I; Martínez C; Pérez-Simón JA; Solano C; Sureda A; Sierra J; Sampol A; Caballero D;
Bone Marrow Transplant; 2021 Aug; 56(8):1919-1928. PubMed ID: 33767400
[TBL] [Abstract][Full Text] [Related]
31. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
Steinmetz TH; Singh M; Lebioda A; Fink L; Schoehl M; Rieth A; Gonzalez-McQuire S; Engelhardt M
J Med Econ; 2021; 24(1):114-122. PubMed ID: 33390079
[TBL] [Abstract][Full Text] [Related]
32. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
33. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis.
Borchmann P; Heger JM; Mahlich J; Papadimitrious MS; Riou S; Werner B
Oncol Ther; 2023 Mar; 11(1):65-81. PubMed ID: 36447041
[TBL] [Abstract][Full Text] [Related]
34. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
[No Abstract] [Full Text] [Related]
35. Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma.
Iqbal M; Castano YG; Paludo J; Rosenthal A; Li Z; Beltran M; Moustafa MA; Inwards D; Porrata L; Micallef I; Bisneto JCV; Johnston P; Ansell SM; Reeder C; Murthy H; Roy V; Foran J; Tun HW; Kharfan-Dabaja MA; Ayala E
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e89-e95. PubMed ID: 34593359
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
37. Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience.
Osmani AH; Khafaga Y; Rauf MS; Maghfoor I; Akhtar S
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e149-e160. PubMed ID: 34627735
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
